Annual Report
Our Mission
enable our customers
make the world
healthier cleaner and safer
Thermo Fisher Scientific the world leader serving
science generating more than billion annual revenues
Customers worldwide trust the technologies and solutions
available through our premier brands help them accelerate
innovation and enhance productivity
Dear Shareholder
all measures Thermo Fisher Scientific
achieved another outstanding year
continued successfully execute our
growth strategy the best partner for our
customers made progress enhancing our
culture great place work for our
colleagues And extended our long track
record delivering strong financial performance
Without the dedication our team none
these accomplishments would possible and
humbled their steadfast commitment
our company growth and success
Starting with our financial scorecard our primary
metric success consistently deliver strong
growth adjusted earnings per share EPS
and pleased report that did again
Our GAAP diluted EPS increased
percent for the full year and our
adjusted EPS increased percent
Our adjusted operating income increased
percent with adjusted operating margin
percent also generated record free
cash flow billion
the top line grew revenues percent
billion for the full year The dynamics
our key end markets were favorable overall and
our team did excellent job leveraging our
industry leading capabilities drive growth
the same time successfully completed and
Marc Casper
President and CEO
revenues
Adjusted earnings per share adjusted operating margin adjusted operating income and free
cash flow are non GAAP financial measures that exclude certain items For reconciliation
these non GAAP financial measures comparable GAAP measures see the accompanying
consolidated statement income pages and this annual report
Annual Report
Strong Track Record
integrated several acquisitions complement
our capabilities expand our customer offering and
strengthen our strategic position
Performance
Inspiring Mission
dollars
GAAP EPS
Adjusted EPS
Thermo Fisher the world leader serving science
such measure success not just our
financial performance but also the way are
making difference the world for our customers
our colleagues and our communities
Our Mission company enable our
customers make the world healthier cleaner and
safer Whether they discovering new treatments for
disease understanding climate change protecting
citizens from harm our customers rely Thermo
Fisher help them find answers some the most
pressing issues our time Everything starts
with our customers because right them
all our stakeholders will benefit
The daily headlines are constant reminder that
live ever changing and ever challenging world
today environment our customers expect more
from This inspires the company they
trust deliver the best solution and time and
again because follow simple growth strategy
Continuously develop high impact innovative
products and services
Adjusted EPS defined page
Leverage our global scale high growth emerging
markets and
Deliver unique customer value proposition
This proven formula positions serve our
customers well today and for years come and
use framework cover some the many
highlights from the year
Breakthrough Innovation
spend
thermofisher
The first element our growth strategy our
ongoing commitment innovation Since our
company founding innovation has remained
important differentiator for spent
nearly million research and development
far more than any company our industry
use this investment help our customers achieve
their goals for innovation and productivity and
enable exciting breakthroughs that will benefit
society large
Enabling targeted
therapies
When comes beating cancer now know that onesize fits all approach doesn work well Our technologies
are propelling revolution diagnosis and treatment
advancing precision medicine
One example our Ion Torrent Oncomine Target Test
for non small cell lung cancer companion diagnostic that
uses our next generation sequencing technology helps
doctors identify the best therapy for individual patients based
their unique molecular profiles continue expand
our Oncomine menu tests keep pace with advances
clinical oncology research
From molecule
medicine
More targeted therapies promise significantly
improve patient lives but they also create complexity for
pharmaceutical and biotechnology companies challenged
with bringing new treatments market quickly yet
cost effectively
Thermo Fisher significantly strengthened its
leading offering for these customers with the acquisition
Patheon provider contract development and
manufacturing services combining Patheon
capabilities with our clinical trials services can take
drug through formulation development commercial
production partnering with our customers deliver
critical medicines patients
Complementary
Segments
Analytical Instruments
Life Sciences Solutions
Revenue
Laboratory
Products Services
Specialty Diagnostics
Revenue
Profile
Diagnostics Healthcare
Pharma Biotech
Markets
Industrial Applied
Academic Government
Services
Products
Consumables
Instruments
Equipment Software
Asia Pacific
Rest World
Europe
Regions
North America
For example combat cancer and other diseases
life science researchers are trying better understand the structure and function proteins our
body New systems such our Thermo Scientific
Krios cryo transmission electron microscope are
revolutionizing structural biology fact the
winners the Nobel Prize Chemistry worked
with our cryo electron microscopy systems
And our leading Thermo Scientific Orbitrap mass
spectrometry platform has been game changer
protein research for many years continued
build that legacy with the launch our Thermo
Scientific Exactive system
Another exciting opportunity precision medicine
are helping scientists design therapies based
individual genetic profile doctors can
match the right therapy patient specific type
cancer were especially proud play role two
medical breakthroughs during the year Our Invitrogen
Dynabeads technology enabled the first CAR cell
therapy for childhood leukemia approved the
Food and Drug Administration FDA And our
Ion Torrent Oncomine Target Test for non smallcell lung cancer screening was the first companion
diagnostic based next generation sequencing
receive FDA clearance
also continued strengthen our offering
specialty diagnostics giving doctors faster and more
accurate information make the right decisions for
their patients highlight from the year was receiving
clearance from the FDA expand the use
our BRAHMS PCT sensitive KRYPTOR assay
prevent the overuse antibiotic therapies
Innovation digital science another compelling
opportunity for We creating digital platform
that helps our customers manage data run their labs
and collaborate more efficiently For example we
connecting instruments the cloud everything
from electronic pipettes our most sophisticated
analytical tools And continue expand our web
presence with percent increase commerce
revenues Our customers want use new
digital tools create more impact through their work
and Thermo Fisher the best position lead this
important trend
Annual Report
Global Scale
The second element our growth strategy involves
leveraging our industry leading scale serve our
customers high growth emerging markets such
China India and the Middle East Emerging markets
represented percent our total revenues
and continued increase our presence meet
our customers evolving needs
India for example we supporting the growing
pharmaceutical industry and the country focus
improving food safety the Middle East we
collaborating with academic and government
customers broaden the use our advanced
technologies from cryo systems for life
science research genetic analysis instruments
for human identification
total revenues
Our greatest success story emerging markets
continues China which represents percent
our company total revenues Our China strategy
aligned with the country year plan placing
emphasis precision medicine environmental
protection and food safety
opened Precision Medicine Customer
Experience Center Guangzhou the center
healthcare innovation China addition serving
showcase our capabilities the facility hub
for customer training collaboration and applications
development also expanded our leading
offering air quality products China acquiring
complementary technologies help our customers
comply with rapidly evolving environmental standards
continue have great momentum China
and other emerging markets and our targeted
investments there will fuel our long term growth
Unique Value
Finally the third element our growth strategy
the unique value proposition can deliver our
customers leveraging our capabilities across the
thermofisher
company continued enhance our offering
through combination internal developments and
strategic acquisitions that complement our strengths
invested billion strategic
The most significant was our addition Patheon
leading contract development and manufacturing
organization CDMO for pharma and biotech
customers Through its comprehensive services
offering from initial drug formulation development
commercial production the business vital
partner biopharma helping deliver medicines
patients adding these capabilities our
leading clinical trials services we created
billion services business that supports our
largest customer base
had the chance welcome many our
new colleagues during Day One celebrations
and visits their sites It been great see the
enthusiasm about being part Thermo Fisher and
the shared excitement over new opportunities this
combination will bring
Whether large small acquired businesses create
the most value when their cultures and capabilities
are smoothly integrated This where our Practical
Process Improvement PPI Business System gives
distinct advantage ingrained across our
company set new standards for operational
excellence quality and productivity and ultimately
promotes customer allegiance Our PPI Business
System also serves playbook for successfully
integrating new businesses Our formula for creating
value from acquisitions make sure that one plus
one equals more than two and our PPI Business
System critical achieving that goal
Vibrant Culture
When serve our customers well build strong
and growing company that creates opportunities for
our colleagues have been part Thermo Fisher
Scientific for years and have always been
inspired the company Mission and our potential
make real difference the world When travel
our sites it also evident that our Values
Integrity Intensity Innovation and Involvement are not
just words but the heart our culture continue
build this foundation attract and retain
exceptional team
Understanding
climate change
According NASA the earth warming
unprecedented rate And understand what means for
the future our planet have look back Thermo
Fisher has joined the global ICE MEMORY initiative help
scientists find answers that lie ancient glacial ice cores
Led the Fondation Universit Grenoble Alpes this
initiative involves extracting ice cores from mountain
glaciers Our spectrometry and chromatography
instruments are then being used analyze the ice
samples gain insight into what the future holds
Uncovering the truth
Solving crimes can present complex challenges
especially when evidence scarce Our human
identification HID technologies help forensics scientists
extract critical DNA evidence that can bring criminal
justice free the wrongly accused
fact our human DNA profiling kits and instruments
helped exonerate two men the who had spent
years behind bars before their murder convictions were
overturned Our range HID systems are used globally
solve crimes find missing children and identify victims
natural disasters
especially proud our progress becoming
more diverse and inclusive culture where
different ways thinking are respected valued
and encouraged Every year the feedback from
our Employee Involvement Survey tells what
we doing well and where can improve The
three survey indexes that measure our progress
Leadership Involvement and Inclusion all showed
improvement again and our Inclusion score
was the highest the three This result our
emphasis modeling behaviors that foster diversity
thought across all career levels job families and
demographics
Our network Employee Resource Groups which
has grown more than chapters worldwide
has been instrumental promoting this aspect
our culture Through these employee led groups
individuals can embrace their differences learn from
each other and have the confidence bring their true
selves work
employees
were pleased recognized externally
including achieving perfect score from the
Corporate Equality Index for the third year row
one the Best Places Work for LGBTQ Equality
were also included the Top Innovators
Diversity and Inclusion the women social
platform Mogul and recognized one the
Best Companies Work For the Women
Choice Awards
Every year take deliberate actions even
better place work When talented colleagues
choose join stay and grow their careers Thermo
Fisher our customers win and Our cultural
evolution very intentional and strengthens our
competitive advantage year after year
our operations while developing innovative solutions
help our customers achieve their own sustainability
goals Second our philanthropic charter centered
STEM education science technology engineering
and math and donate considerable time and
money inspire students take interest
these subjects Last encourage our teams
involved through volunteer activities organized our
Community Action Councils and many other outreach
programs global scale
was especially moved the response our teams
when the hurricanes hit our facilities Puerto Rico
last fall was inspiring see the outpouring
supplies and donations from colleagues around the
world Local teams set shelters our facilities
and some cases managers went house tohouse find their missing colleagues spite
tremendous hardship they worked tirelessly get
our operations back online serve our customers
and deliver critical medicines patients
Examples like these are what make our company
special place and they assure that our best years
are still ahead Our long term vision for Thermo Fisher
not only great company but great
enduring company the eyes our customers our
colleagues the communities which operate
and the shareholders who invest our future Every
successful year keeps solidly that course
Sincerely
Marc Casper
President and CEO
February
It also important that our culture Involvement and
Inclusion extends into our communities encourage
you read about the great progress we made
our recent corporate social responsibility CSR
report Our CSR strategy threefold First are
committed minimizing the environmental impact
Annual Report
Consolidated Statement Income
addition the financial measures prepared accordance with generally accepted
accounting principles GAAP use certain non GAAP financial measures including
adjusted EPS adjusted operating income and adjusted operating margin which
exclude certain acquisition related costs including charges for the sale inventories
revalued the date acquisition and significant transaction costs restructuring
and other costs income and amortization acquisition related intangible assets
Adjusted EPS also excludes certain other gains and losses that are either isolated
cannot expected occur again with any predictability tax provisions benefits
related the previous items benefits from tax credit carryforwards the impact
significant tax audits events and the results discontinued operations
exclude the above items because they are outside our normal operations and
millions except per share amounts
certain cases are difficult forecast accurately for future periods also use
non GAAP measure free cash flow which operating cash flow excluding net
capital expenditures and also excludes operating cash flows from discontinued
operations provide view the continuing operations ability generate cash
for use acquisitions and other investing and financing activities believe that
the use non GAAP measures helps investors gain better understanding
our core operating results and future prospects consistent with how management
measures and forecasts the company performance especially when comparing
such results previous periods forecasts The non GAAP measures presented
herein are not meant considered superior substitute for our results
operations prepared accordance with GAAP
Consolidated Statement Income
Revenues
Costs and Operating Expenses
Cost revenues
Selling general and administrative expenses
Amortization acquisition related intangible assets
Research and development expenses
Restructuring and other costs income net
Operating Income
Other Expense Net
Income from Continuing Operations Before
Income Taxes
Income Tax Provision Benefit
Income from Continuing Operations
Loss from Discontinued Operations net income tax
benefit and
Basic
Diluted
Basic
Diluted
Net Income
Earnings per Share from Continuing Operations
Earnings per Share
Weighted Average Shares
Basic
Diluted
Reconciliation Adjusted Earnings per Share
GAAP Diluted EPS
Cost Revenues Charges Net Tax
Selling General and Administrative Charges
Net Tax
Restructuring and Other Costs Income Net Tax
Amortization Acquisition related Intangible Assets
Net Tax
Other Expense Income Net Tax
Income Tax Benefit Provision
Discontinued Operations Net Tax
Adjusted EPS
thermofisher
Dollars millions
Reconciliation Adjusted Operating Income and Adjusted Operating Margin
GAAP Operating Income
Selling General and Administrative Charges Net
Restructuring and Other Costs Income Net
Cost Revenues Charges
Amortization Acquisition related Intangible Assets
Adjusted Operating Income
Reconciliation Free Cash Flow
GAAP Net Cash Provided Operating Activities
Net Cash Used Discontinued Operations
Purchases Property Plant and Equipment
Proceeds from Sale Property Plant and Equipment
Free Cash Flow
GAAP reported results were determined accordance with generally accepted accounting principles GAAP
Adjusted results are non GAAP measures and for income measures exclude certain charges cost revenues see note for details certain charges credits
selling general and administrative expenses see note for details amortization acquisition related intangible assets restructuring and other costs income net
see note for details certain other gains losses that are either isolated cannot expected occur again with any predictability see note for details the tax
consequences the preceding items and certain other tax items see note for details and results discontinued operations
Reported results include and and respectively charges for the sale inventories revalued the date
acquisition and and respectively accelerated depreciation manufacturing assets abandoned due
facility consolidations and and and respectively charges conform the accounting policies recently acquired businesses
the company accounting policies
Reported results include and and respectively third party transaction integration costs related acquisitions
and and respectively charges credits net for changes estimates contingent acquisition consideration
and and respectively income charges net associated with product liability litigation and
and respectively accelerated depreciation fixed assets abandoned due integration synergies and facility consolidations and
and and respectively charges conform the accounting policies recently acquired businesses the company accounting policies
Reported results include restructuring and other costs income net consisting principally severance abandoned facility and other expenses headcount reductions
within several businesses and real estate consolidations and and respectively net credits charges for litigation related matters
and and respectively compensation contractually due employees acquired businesses hurricane response impairment costs
environmental remediation costs and and respectively net gains losses sales product lines and real
estate and settlement curtailment retirement plans impairment intangible assets gains the sale businesses principally the
sera and media gene modulation magnetic beads and Cole Parmer businesses and charges for cash compensation monetize certain equity awards
held employees acquired businesses the date acquisition
Reported results include and and respectively charges related fees paid obtain bridge financing commitments for
acquisitions and and respectively losses the early extinguishment debt and and
respectively net gains investments and and respectively amortization acquisition related intangible assets for the
company equity investments and costs associated with entering into interest rate swap agreements
Reported income tax provision includes and and respectively incremental tax benefit for the pretax reconciling items between GAAP and adjusted net income net provision from the effects tax reform legislation consisting primarily the
transition tax deemed repatriated earnings foreign subsidiaries net benefit from adjusting the deferred tax balances for the rate reduction
and and respectively incremental tax benefit provision from adjusting the company deferred tax balances result tax
rate changes and and and respectively incremental tax provision due the net impact tax audits
Free cash flow and was reduced and respectively cash outlays related the acquisition Life Technologies including monetizing
certain equity awards severance obligations third party transaction integration costs and fees obtain bridge financing commitments
Annual Report
Shareholder Services
Shareholders Thermo Fisher Scientific who desire information about the company
are invited contact the Investor Relations Department Thermo Fisher Scientific
Inc Third Avenue Waltham You may also send
email investorrelations thermofisher Material interest shareholders
available from the company website thermofisher under About then
Investors
Stock Transfer Agent
The stock transfer agent for Thermo Fisher Scientific AST maintains shareholder
activity records The agent will respond questions issuance stock
certificates change ownership lost stock certificates and change address
For these and similar matters please direct inquiries AST Avenue
Brooklyn You may also send email
info astfinancial visit the transfer agent website astfinancial
Annual Meeting
The annual meeting shareholders will held Wednesday May
the Mandarin Oriental New York Columbus Circle Street
New York
Annual Report Form
The accompanying Annual Report Form for the fiscal year ended December
does not contain exhibits Exhibits have been filed with the Securities and
Exchange Commission Upon request the Investor Relations Department the
company will furnish without charge any such exhibits well copies periodic
reports filed with the Securities and Exchange Commission
Forward Looking Statements
This annual report contains forward looking statements within the meaning
Section the Securities Exchange Act Any statements contained
herein that are not statements historical fact may deemed forwardlooking statements including without limitation statements regarding projections
revenue expenses earnings margins tax rates tax provisions cash flows
pension and benefit obligations and funding requirements our liquidity position
cost reductions restructuring activities new product and service developments
competitive strengths market position acquisitions divestitures growth
declines and other trends markets sell into new modified laws regulations
and accounting pronouncements outstanding claims legal proceedings tax audits
and assessments and other contingent liabilities foreign currency exchange rates
and fluctuations those rates general economic and capital markets conditions
the timing any the foregoing assumptions underlying any the foregoing
and any other statements that address events developments that Thermo Fisher
intends believes will may occur the future Without limiting the foregoing the
words believes anticipates plans expects seeks estimates and similar
expressions are intended identify forward looking statements although not all
forward looking statements are accompanied such words While the company
may elect update forward looking statements the future specifically disclaims
any obligation even the company estimates change and readers
should not rely those forward looking statements representing the company
views any date subsequent the date the filing this report
number important factors could cause the results the company differ
materially from those indicated such forward looking statements including those
detailed under the heading Risk Factors Part Item the accompanying
Annual Report Form for the fiscal year ended December
thermofisher
Management Team
Marc Casper
Joseph Beery
Mark Stevenson
Michael Boxer
Stephen Williamson
Lisa Britt
Patrick Durbin
Shiraz Ladiwala
Gregory Herrema
Richard Spoor
Syed Jafry
Kenneth Apicerno
Michel Lagarde
Sharon Briansky
Frederick Lowery
Peter Hornstra
President and Chief Executive Officer
Executive Vice President and Chief Operating Officer
Senior Vice President and Chief Financial Officer
Senior Vice President and President Specialty Diagnostics
Senior Vice President and President Customer Channels
Senior Vice President and President Regions
Senior Vice President and President Pharma Services
Senior Vice President and President Life Sciences Solutions
and Laboratory Products
Daniel Shine
Senior Vice President and President Analytical Instruments
Peter Silvester
Senior Vice President and Chief Information Officer
Senior Vice President and General Counsel
Senior Vice President and Chief Human Resources Officer
Senior Vice President Strategy and Corporate Development
Senior Vice President Global Business Services
Vice President Investor Relations
Vice President and Secretary
Vice President and Chief Accounting Officer
Karen Kirkwood
Vice President Corporate Communications
Anthony Smith
Vice President Tax and Treasury and Treasurer
Senior Vice President and President Life Sciences Solutions
Andrew Thomson
Senior Vice President and President Europe Middle East and Africa
Board Directors
Jim Manzi
Chairman the Board Chairman Stonegate Capital
private equity investments Former Chairman
President and Chief Executive Officer Lotus Development
Corporation computer software
Marc Casper
President and Chief Executive Officer
Nelson Chai
President and Chief Executive Officer The Warranty
Group specialty insurance products
Martin Harris
Associate Vice President the Health Enterprise and
Chief Business Officer the Dell Medical School
The University Texas Austin healthcare
Tyler Jacks
David Koch Professor Biology Massachusetts
Institute Technology Director David Koch Institute
for Integrative Cancer Research research
Judy Lewent
Former Executive Vice President and Chief Financial Officer
Merck Inc pharmaceuticals
Thomas Lynch
Chairman the Board Directors
Connectivity Ltd electronics
William Parrett
Former Global Chief Executive Officer
Deloitte Touche Tohmatsu accounting
Lars rensen
Former President and Chief Executive Officer
Novo Nordisk healthcare
Scott Sperling
President Thomas Lee Partners
leveraged buyouts
Elaine Ullian
Former President and Chief Executive Officer
Boston Medical Center healthcare
Dion Weisler
President and Chief Executive Officer
Inc information technology
Thermo Fisher Scientific Inc Third Avenue Waltham USA
thermofisher
